SCHEMBL2541985

SCHEMBL2541985

CC(C)c1ccc(-c2noc(CCl)n2)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 2/20 0.51
SCN5A Q14524 2/20 0.51
SCN10A Q9Y5Y9 2/20 0.51
CYP1A2 P05177 2/20 0.49
SMN1; SMN2 Q16637 4/20 0.48
NPSR1 Q6W5P4 2/20 0.48
TDP1 Q9NUW8 2/20 0.48
SIRT2 Q8IXJ6 3/20 0.47
TSHR P16473 4/20 0.46
MAPK1 P28482 3/20 0.45
ALOX15 P16050 1/20 0.45
NPC1 O15118 2/20 0.44
HTT P42858 2/20 0.44
RAB9A P51151 2/20 0.44
POLB P06746 1/20 0.44
LMNA P02545 1/20 0.44
MAPT P10636 1/20 0.44
ALDH1A1 P00352 1/20 0.43
CYP2D6 P10635 1/20 0.43
CYP2C19 P33261 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10022385 0.85 ACACB (0.56) NOTUMSCN5ASCN10ACYP1A2SMN1; SMN2
SCHEMBL14441200 0.84 MAPK1 (0.54) NOTUMSCN5ASCN10ASMN1; SMN2NPSR1
SCHEMBL6528165 0.84 NOTUM (0.69) NOTUMSCN5ASCN10ACYP1A2SMN1; SMN2
SCHEMBL507782 0.83 NOTUM (0.72) NOTUMSCN5ASCN10ACYP1A2SMN1; SMN2
SCHEMBL201423 0.81 NOTUM (0.56) NOTUMSCN5ASCN10ACYP1A2SMN1; SMN2
SCHEMBL10904042 0.81 SMN1; SMN2 (0.59) SMN1; SMN2NPSR1TDP1TSHRMAPK1
SCHEMBL8245745 0.81 S1PR1 (0.52) NOTUMSCN5ASCN10ACYP1A2SMN1; SMN2
SCHEMBL8432966 0.79 MAPT (0.56) NOTUMCYP1A2SMN1; SMN2TDP1SIRT2
SCHEMBL10905724 0.78 RAB9A (0.56) NOTUMCYP1A2SMN1; SMN2TDP1TSHR
SCHEMBL30566767 0.78 RAB9A (0.56) NOTUMCYP1A2SMN1; SMN2TDP1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11970470-B1 {5-chloro-2-(2-(3-(substitutedphenyl)-1,2,4-oxadiazol-5-yl)ethyl)phenyl}(phenyl)methanones as larvicidal agents King Faisal University (SA) 2024-04-30 US disclosed
EP-1937673-B1 IMIDAZOLE DERIVATIVES AS INHIBITORS OF TAFIA SANOFI SA (FR) 2015-10-21 EP disclosed
US-8044208-B2 inhibit the enzyme TAFIa (activated thrombin-activatable fibrinolysis inhibitor); 3-(6-aminopyridin-3-yl)-2-{1-[5-(5-chlorothiophen-2-yl)isoxazol-3-ylmethyl]-1H-imidazol-4-yl}propionic acid SANOFI-AVENTIS (FR) 2011-10-25 US disclosed
US-20080262028-A1 IMIDAZOLE DERIVATIVES AS INHIBITORS OF TAFIA SANOFI-AVENTIS (FR) 2008-10-23 US disclosed
EP-1937673-A1 IMIDAZOLE DERIVATIVES AS INHIBITORS OF TAFIA Sanofi-Aventis (FR) 2008-07-02 EP disclosed
WO-2007045339-A1 IMIDAZOLE DERIVATIVES AS INHIBITORS OF TAFIA SANOFI-AVENTIS (DE) 2007-04-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080262028-A1 IMIDAZOLE DERIVATIVES AS INHIBITORS OF TAFIA TFPI, TFPI2, TAF1 NOTUM 774/4885SCN5A 2480/4885SCN10A 2365/4885
US-11970470-B1 {5-chloro-2-(2-(3-(substitutedphenyl)-1,2,4-oxadiazol-5-yl)ethyl)phenyl}(phenyl)methanones as larvicidal agents CASP3, CASP2, CASP7 NOTUM 1319/4885SCN5A 3335/4885SCN10A 4289/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.